Skip to Content
Merck

SML2910

Bindarit

≥98% (HPLC)

Synonym(s):

2-((1-Benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid, 2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]propanoic acid, AF 2838, AF2838

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H20N2O3
CAS Number:
130641-38-2
Molecular Weight:
324.37
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
MFCD00866723
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Bindarit, ≥98% (HPLC)

SMILES string

[n]2(nc(c3c2cccc3)COC(C)(C)C(=O)O)Cc1ccccc1

InChI

1S/C19H20N2O3/c1-19(2,18(22)23)24-13-16-15-10-6-7-11-17(15)21(20-16)12-14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3,(H,22,23)

InChI key

MTHORRSSURHQPZ-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Bindarit is an indazolic derivative with anti-inflammatory efficacy in vitro (150-300 μM) and in animal disease models in vivo (100 mg/kg ip, 50 mg/kg po, or 0.5% in chow; rats & mice). Bindarit selectively inhibits LPS-induced CCL2/MCP-1, CCL7/MCP-3, CCL8/MCP-2 chemokines over CCL3/MIP-1α and IL-8/CXCL8 in human monocytes, while blocking CCL2, but not CCL7 or CCL8, induction in HUVECs, and preventing LPS-induced CCL2 & IL-12β/p40 by inhibiting NFκB activation in murine macrophages (BMDM & Raw 264.7). Bindarit is also reported to exhibit non-competitive inhibiory potency against human monocarboxylate transporter MCT4 (Ki = 30.2 μM) over MCT1 (<40% inhibition at 500 μM).
NFκB activation, CCL2 (MCP1) & IL-12β/p40 induction blocker with anti-inflammation efficacy in vivo. Selectively inhibits monocarboxylate transporter MCT4 over MCT1.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000396688
0000396688
0000223830
0000223830
0000106377

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C Zoja et al.
Kidney international, 53(3), 726-734 (1998-03-21)
As an alternative to classical immunosuppressants in experimental lupus nephritis, we looked at bindarit, 2-methyl-2-[[1-phenylmethyl)-1H-indazol-3-y1]methoxy]propanoic acid, a novel molecule devoid of immunosuppressive effects, which selectively reduces chronic inflammation in rat adjuvant arthritis. Two groups of NZB/W mice (N = 55
Massimiliano Mirolo et al.
European cytokine network, 19(3), 119-122 (2008-09-09)
Bindarit is an indazolic derivative that is devoid of any immunosuppressive effects and has no effect on arachidonic acid metabolism. However, it has been proved to have anti-inflammatory activity in a number of experimental diseases, including pancreatitis, arthritis, and lupus
A Guglielmotti et al.
Clinical and experimental rheumatology, 16(2), 149-154 (1998-04-16)
The present study was designed to investigate the effects of bindarit on animal survival and renal damage in murine lupus autoimmune disease. Female NZB/W mice were used. Bindarit was administered, as a 0.5% medicated diet, starting either before the onset
Alina Wiesemann et al.
Antioxidants & redox signaling, 30(2), 213-231 (2018-02-22)
Aims: Radiation-induced normal tissue toxicity often precludes the application of curative radiation doses. Here we investigated the therapeutic potential
Shujun Ge et al.
Journal of neuroinflammation, 9, 171-171 (2012-07-14)
Production of the chemokine CCL2 by cells of the neurovascular unit (NVU) drives critical aspects of neuroinflammation. Suppression of CCL2 therefore holds promise in treating neuroinflammatory disease. Accordingly, we sought to determine if the compound bindarit, which inhibits CCL2 synthesis
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service